Department of Immunology and Center for Inflammation and Cancer, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
J Investig Med. 2011 Oct;59(7):1067-72. doi: 10.2310/JIM.0b013e31820fb28c.
The process of erythropoiesis in the fetal liver and adult bone marrow is regulated by the hormone erythropoietin (Epo), which is produced in the kidney at low levels under homeostatic conditions. Defects in Epo production result in severe anemia; use of recombinant hormone has improved the lives of patients with renal failure or anemia because of bone marrow suppression. Deletion of the Epo gene in mice leads to embryonic lethality at days 13 to 15, coincident with the establishment of definitive (adult-type) erythropoiesis and underscoring the absolute necessity of Epo function in vivo. Epo has proven to be a successful pharmaceutical agent, one of the early triumphs of recombinant protein technology. Because of its clinical importance, a great deal of attention has focused on the molecular mechanisms of Epo-regulated erythropoiesis. This review highlights the basic concepts of Epo signal transduction within the hematopoietic system, the major site of Epo action in vivo.
在胎儿肝脏和成人骨髓中,红细胞生成的过程受激素促红细胞生成素(Epo)的调节,Epo 在低水平下由肾脏产生,以维持体内平衡。Epo 产生缺陷会导致严重贫血;重组激素的使用改善了肾衰竭或骨髓抑制导致贫血的患者的生活。在小鼠中删除 Epo 基因会导致胚胎在第 13 至 15 天死亡,这与明确的(成人型)红细胞生成的建立相吻合,突出了 Epo 在体内功能的绝对必要性。Epo 已被证明是一种成功的药物制剂,是重组蛋白技术的早期成功之一。由于其临床重要性,人们对 Epo 调节的红细胞生成的分子机制给予了极大关注。这篇综述强调了 Epo 在造血系统中的信号转导的基本概念,这是 Epo 在体内的主要作用部位。